There are currently 60 active clinical trials seeking participants for Rheumatoid Arthritis research studies. The states with the highest number of trials for Rheumatoid Arthritis participants are Florida, California, Texas and Pennsylvania.
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +50 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Recruiting
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD
Recruiting
The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina
Conditions: Rheumatoid Arthritis
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Anniston Medical Clinic, Anniston, Alabama +16 locations
Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona +187 locations
Conditions: Rheumatoid Arthritis
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Recruiting
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Inland Rheumatology Clinical Trials, Inc. Site Number : 8400004, Upland, California +54 locations
Conditions: Rheumatoid Arthritis
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Recruiting
In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites. The current study will determine whether or not the addition of anti-inflammatory diet improves the clinical outcomes in participants with rheumatoid arthritis, and the role of microbiome and circulating metabolites.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: UCSD, La Jolla, California
Conditions: Rheumatoid Arthritis
Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
Recruiting
Background: Inflammation can play a role in diseases like heart disease and rheumatoid arthritis. PET scans can help detect inflammation. Two new drugs may create better PET images. Objective: To see if the drugs [11C]ER176 and [11C]MC1 can help image inflammation. Eligibility: People ages 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM). Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed. Design: Healthy participants will be sc... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/03/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Denver Hip & Knee, Inc., Parker, Colorado +14 locations
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Recruiting
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/29/2024
Locations: University of California San Francisco, San Francisco, California +3 locations
Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)
Recruiting
Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis (RA).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/24/2024
Locations: Medvin Clinical Research//Amicus Arthritis, Whittier, California
Conditions: Rheumatoid Arthritis
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
Recruiting
This study is a comparison of quantitative Tc 99m tilmanocept imaging with IHC analysis of CD206 expression in synovial tissue of RA subjects.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Attune Health, Los Angeles, California +3 locations
Conditions: Rheumatoid Arthritis